For the First Time in Kolkata: HCG Leads the Way with Robofusion 2025, Redefining Surgical Training
Kolkata, August 12th 2025: HCG Cancer Centre, Kolkata successfully hosted Robofusion 2025, a two-day hands-on robotic surgery program on 8th & 9th August designed for trained surgeons, Gynecologists, Head & Neck, GI and urologists, accredited by the West Bengal Medical Council. The initiative aimed to generate interest in robotic-assisted surgery particularly among cancer care specialists by highlighting its clinical advantages and encouraging its adoption in everyday practice.
Through this program, HCG strived to bridge the gap between theoretical knowledge and real-world application of robotic surgery, with an emphasis on understanding disease-specific nuances and enhancing patient outcomes.
The first day included interesting presentations and robotic surgical video walkthroughs by an expert group of specialists from HCG Cancer Centre Kolkata. Dr. Rajeev Sharan, Dr. Gaurav Aggarwal, Dr. Karan Sehgal, Dr Dharmendra Kumar Rai, Dr. Suvraraj Das. The interactive format encouraged participants to raise questions and deepen their understanding of robotic precision techniques. Other key dignitaries from HCG included, Mr. Prateek Jain, Regional Business Head – East & AP, Healthcare Global Enterprises Limited and Dr. Amarjeet Singh, Chief Operating Officer at HCG Cancer Centre, Newtown, Kolkata. During the day-long program, participating surgeons also visited HCG Cancer Centre facility for a supervised dry lab session.
The second day was at HCG Cancer Centre, Newtown, Kolkata which featured a day long practical hands on wet lab session, where surgeons honed their skills on animal tissue using the Da Vinci X robotic system, closely guided by seasoned experts.
This marked the first time in Eastern India, that such a program on hands-on oncology wet lab for practicing surgeons has been conducted. The program aimed to bridge the gap between theoretical understanding and real-world application of robotic-assisted surgery, helping clinicians appreciate its relevance in managing complex disease profiles and delivering improved patient outcomes.
Dr. Rajeev Sharan, HOD & Sr Consultant, Head and Neck Oncology & Robotics, HCG Cancer Centre, Kolkata, said, “Training practicing surgeons in robotic systems is no longer optional—it’s essential. At HCG, we understand that many experienced clinicians may not have had structured access to robotic platforms during their academic or early career years. Through Robofusion, we’ve created a unique hands-on opportunity for them to upskill in precision, control, and minimally invasive techniques—competencies that are increasingly vital in delivering advanced, patient-centric surgical care.”
Dr. Gaurav Aggarwal, HOD & Sr Consultant, Uro-Oncology & Robotics, HCG Cancer Centre, Kolkata, shared, “Witnessing the curiosity and engagement of trained surgeons as they explored robotic surgery first-hand was truly encouraging. For many, this was their first direct experience with such cutting-edge technology. At HCG, we aim to bridge the gap between traditional surgical training and the evolving possibilities of robotic platforms. This workshop wasn’t just about technology—it was about advancing skill sets, refining techniques, and fostering a forward-thinking approach to patient care.”
Dr. Karan Sehgal, Associate Consultant, Surgical Oncology & Robotics, HCG Cancer Centre, Kolkata, stated, “Introducing young surgeons to robotic platforms at this stage in their training expands how they think about surgery itself. It shifts their approach from manual precision to technology-assisted finesse. With tools like the Da Vinci X, they begin to understand how minimally invasive techniques can translate to better outcomes and faster recovery for patients — lessons that will shape every clinical decision they make going forward.”
Robofusion 2025 concluded with resounding success, reaffirming HCG Cancer Centre as a frontrunner in not only delivering advanced oncological care but also shaping the future of surgical education. By bridging the gap between theory and technology, HCG continues to empower the next generation of surgeons with tools, insights, and experiences that will define the future of minimally invasive cancer treatment.